{
    "nctId": "NCT00120939",
    "briefTitle": "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer",
    "officialTitle": "Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* At least 18 years old\n* Metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme\n* ECOG performance status score either 0, 1, or 2\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Greater than two prior cytotoxic regimens\n* Laboratory values showing adequate function of bone marrow, liver, and kidneys\n* Uncontrolled hypertension\n* Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}